BioMarin Stock Surges on Strong Q4 Results and Guidance

BioMarin Pharmaceutical Inc. (BMRN) stock traded higher on Thursday following the company's release of strong fourth-quarter and full-year 2024 financial results, as well as its guidance for 2025. The company reported adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus estimate of 53 cents. Additionally, BioMarin reported sales of $747.31 million, surpassing the consensus estimate of $713.44 million. The company's total revenues increased by 16% year-over-year, driven by strong contributions from Voxzogo in all regions. Revenues from BioMarin's Enzyme Therapies also increased by 9% compared to the same period last year, driven by increased patient demand in all regions and the timing of large government orders in certain regions outside the U.S.